Post-transplant lymphoproliferative disorder in adult renal transplant recipients: survival and prognosis

References

• Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010;149:693.
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Trappe RU. EBV and posttransplantation lymphoproliferative disease: what to do? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program; doi: 10.1182/asheducation-2013.1.95. ASH Education Book December 6, 2013 vol. 2013 no. 1 95–102.
   Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076.
   PubMed Web of Science ®Google Scholar
• Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg 2005;5:775.
   Google Scholar
• Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010;149:675.
   PubMed Web of Science ®Google Scholar
• Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196.
   PubMed Web of Science ®Google Scholar
• Shipp MA. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993;329:987.
   Google Scholar
• Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007;86:599.
   PubMed Web of Science ®Google Scholar
• Glotz D, Chapman JR, Dharnidharka VR, et al. The Seville expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation 2012;94:784.
   PubMed Web of Science ®Google Scholar
• Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:1302.
   PubMed Web of Science ®Google Scholar
• Morton M, Coupes B, Roberts SA, et al. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Transplantation 2013;95:470.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247.
   Google Scholar
• Lewington AKS. Acute kidney injury. Clinical practice guidelines. 5th ed. UK Renal Association. Renal Association (epublication) www.renal.org/guidelines/modules/acute-kidney-injury; 2011.
   Google Scholar
• Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol Off J Am Soc Clin Oncol 2001;19:772.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005;46:191.
   PubMed Web of Science ®Google Scholar
• Hourigan MJ, Doecke J, Mollee PN, et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Haematol 2008;141:904.
   PubMed Web of Science ®Google Scholar
• Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:1038.
   PubMed Web of Science ®Google Scholar
• Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg 2012;12:682.
   Google Scholar
• Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222.
   PubMed Web of Science ®Google Scholar
• Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005;80:193.
   PubMed Web of Science ®Google Scholar
• Michonneau D, Suarez F, Lambert J, et al. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrol Dial Transplant. 2013 Feb;28(2):471–8. doi: 10.1093/ndt/gfs476. Epub 2012 Nov 4. p 214.
   PubMed Web of Science ®Google Scholar
• Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011 Feb;11(2): 336–47. doi: 10.1111/j.1600-6143.2010.03387.x. Epub 2011 Jan 10.
   PubMed Web of Science ®Google Scholar
• Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol Off J Am Soc Clin 2009;27:3354.
   PubMed Web of Science ®Google Scholar
• Trappe R, Hinrichs C, Appel U, et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg 2009;9:2331.
   Google Scholar
• Cartron G, Trappe RU, Solal-Céligny P, et al. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res Off J Am Assoc Cancer Res 2011;17:19.
   PubMed Web of Science ®Google Scholar
• Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol (Stockholm, Sweden) 2014;53:669.
   PubMed Web of Science ®Google Scholar
• Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg 2006;6:2735.
   Google Scholar
• Podoltsev N, Zhang B, Yao X, et al. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk 2013;13:716.
   PubMed Web of Science ®Google Scholar
• Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2010;53:961.
   Web of Science ®Google Scholar
• Choquet S, Varnous S, Deback C, Garg AX, Parikh CR. Adapted treatment of Epstein-Barr Virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation. Am J Transpl 2014;14:857.
   PubMed Web of Science ®Google Scholar